Learning and research

Porto-pulmonary hypertension (PoPH) represents a rare but significant form of pulmonary arterial hypertension (PAH) in children.

Fibrotic lung diseases are often characterized by chronic inflammation and the progressive destruction of the vasculature, parenchyma, and airways, leading to cellular metabolic changes. 

Pulmonary hypertension (PH) is a severe complication observed in pediatric patients after hematopoietic cell transplantation or chemotherapy.

This systematic review and meta-analysis evaluated the performance of machine learning (ML) models in predicting mortality among pulmonary embolism (PE) patients, synthesizing data from 17 studies encompassing 844,071 cases.

In this PH Community Call we discussed: 

• Adventitial fibroblasts direct smooth muscle cell-state transition in pulmonary vascular disease
• Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis 

Adhesive reactions are common complications of continuous treprostinil infusions, limiting their recommended use as a treatment for severe pulmonary hypertension.

Pulmonary hypertension (PHTN) in infants with developmental lung disease, such as bronchopulmonary dysplasia (BPD), chronic lung disease of infancy (CLD), or congenital diaphragmatic hernia (CDH), can be exacerbated by atrial septal shunts secondary to atrial septal defects (ASD).

The activin signaling inhibitor sotatercept was approved for Group 1 pulmonary arterial hypertension (PAH) based on Phase 2 and 3 clinical trials showing significant improvements in primary outcomes; reduced pulmonary vascular resistance (PVR) and increased 6-min walk distance (6MWD), respectively.

The Women's Health Task Force was relaunched to address the intersection of women's health and pulmonary vascular disease. The webinar includes research presentations on sex differences and sex hormone treatments in pulmonary arterial hypertension (PAH). Studies show that this disease primarily affects women, but men have worse survival. There has been significant research on the role of sex hormones in this disparity including the phase 3 trial of anastrozole that was presented. The Women's Health Task Force aims to improve knowledge, encourage research, and optimize delivery of clinical care to women with pulmonary vascular disease, with future events planned to foster global collaboration on women's health and pulmonary hypertension.